TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00011999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02675881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSM
Description: Monopolar RFA using dual switching mode (DSM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: separable clustered electrode
Description: A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
Study: NCT03323021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion/chorion membrane
Description: dehydrated human amnion/chorion membrane

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT04803032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial parotidectomy
Description: The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
Study: NCT00661037

Intervention type: DEVICE
Intervention: Implantable defibrillator
Description: Implantable defibrillator to reduce ventricular arrhythmias via shock.

Intervention type: DEVICE
Intervention: Implantable defibrillator
Description: Implantable defibrillator to reduce ventricular arrhythmias via shock.
Study: NCT01529697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Feedback
Description: The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Feedback
Description: The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
Study: NCT00322530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal replacement therapy
Description: ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal replacement therapy
Description: ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
Study: NCT01959984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100g Standard Noodles
Description: Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 75g Oral Glucose
Description: Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
Study: NCT01282879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
Study: NCT00592137

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: C (smoothies based on soy protein containing no additional calcium)
Description: Two smoothies per day based on soy protein containing no additional calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B (smoothies based on soy protein containing calcium)
Description: Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A (smoothies based on dairy protein containing calcium)
Description: Two smoothies daily based on dairy protein containing 650 mg calcium
Study: NCT03664570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN Balloon Catheter
Description: The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN Balloon Catheter
Description: The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN Balloon Catheter
Description: The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
Study: NCT01175408

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Blood Glucose Monitoring
Description: The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG With Knowledge
Description: The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
Study: NCT04182386

Intervention type: PROCEDURE
Intervention: Portal vein embolization
Description: Selective preoperative portal vein embolization

Intervention type: PROCEDURE
Intervention: Portal vein embolization
Description: Selective preoperative portal vein embolization
Study: NCT02670356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: two 750 mg/capsules/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: one 300 mg capsule/day
Study: NCT02406066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metyrapone & oxazepam
Description: 6 subjects will receive active study drug (a low dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metyrapone & oxazepam
Description: 6 subjects will receive active study drug (a medium dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metyrapone & oxazepam
Description: 6 subjects will receive active study drug (a high dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each cohort will have 2 subjects receiving placebo
Study: NCT04634565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: oral PF-06651600 tablet 200 mg once daily
Study: NCT03186287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric training
Description: Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric training
Description: Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
Study: NCT01988675

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI) Assessments
Description: MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI) Assessments
Description: MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
Study: NCT03109184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project STRONG
Description: The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
Study: NCT01042925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: administered orally once daily as tablet(s)
Study: NCT03186287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy
Description: The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy
Description: The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
Study: NCT00822237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)
Description: VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)
Description: VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live (MMR)
Description: M-M-R II in two 0.5 mL doses by injection \~6 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live (MMR)
Description: M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
Study: NCT00650806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
Study: NCT01042925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: administered orally once daily as tablet(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: administered by IV once every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: administered by IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: administered by IV once every week
Study: NCT03686735

Intervention type: OTHER
Intervention: 5 anchors and numbers
Description: How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had

Intervention type: OTHER
Intervention: 5 anchors and no numbers
Description: How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had

Intervention type: OTHER
Intervention: Visual analog scale with 3 anchors and numbers
Description: How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit

Intervention type: OTHER
Intervention: Visual analog scale with 3 anchors and no numbers
Description: How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had
Study: NCT01056939

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)
Description: Treatment with neurally adjusted ventilatory assist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)
Description: Treatment with PC or PRVC ventilation.
Study: NCT01236521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological (MED)
Description: During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (CBT)
Description: There will be 8 sessions of pain self-management and coping skills.
Study: NCT02856048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin (GnRHa) + Chemotherapy
Description: During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
Study: NCT00615017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773 (CytoFab)
Description: intravenous infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773 (CytoFab)
Description: intravenous infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773 (CytoFab)
Description: intravenous infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773 (CytoFab)
Description: intravenous infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773 (CytoFab)
Description: intravenous infusions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00806988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral Valve Repair
Description: Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~1. All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~2. The heart will be arrested with cardioplegia.~3. A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings.
Study: NCT04249128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keratin
Description: Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keratin
Description: Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keratin
Description: Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keratin
Description: Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ceramides
Description: Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ceramides
Description: Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ceramides
Description: Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ceramides
Description: Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
Study: NCT00806988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
Study: NCT01880892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PH probe Testing
Description: 24 hour PH probe testing, which will measure acid reflux following cricopharyngeal myotomy.
Study: NCT01654640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 500mg p.o. bid for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for metformin)
Description: placebo 1T bid
Study: NCT02146794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal denervation